The "North America RNA Therapeutics Market, By Country, Competition, Forecast & Opportunities, 2019-2029F" report has been ...

Most people don't enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such as those made from messenger RNA (mRNA), that can be sprayed and inhaled. A ...

In a report released yesterday, Luca Issi from RBC Capital maintained a Hold rating on Sangamo Biosciences (SGMO – Research Report), with ...

Issi covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, BioMarin Pharmaceutical, and Moderna. According to TipRanks ... and commercialization of nucleic acid-based therapeutics.

December S&P 500 E-Mini futures (ESZ24) are up +0.27%, and December Nasdaq 100 E-Mini futures (NQZ24) are up +0.33% this morning, extending their post-Election Day gains, while investors looked ahead ...

Amazon One Medical is expanding its telehealth services with the launch of upfront and low-cost treatment plans and ...

"Vergent concludes enrolment for lung cancer study of VGT-309" was originally created and published by Clinical Trials Arena, ...

In this article, we will discuss the 12 High Growth Large Cap Stocks to Buy Now. BlackRock highlighted that its portfolio ...

FDA accepts BLA resubmission of pz-cel in recessive dystrophic epidermolysis bullosa and sets PDUFA target action date of April 29, 2025 Company makes significant progress toward potential commerciali ...

BX211 Phase 2 for treatment of Diabetic Foot Osteomyelitis (DFO) patient enrollment completed and on track to report topline results in Q1 2025 BX004 Phase 2b study in Cystic Fibrosis (CF) is now ...

Arbutus has moved into Part 3 of this clinical trial which evaluates repeat dosing of AB-101 for 28 days in patients with cHBV and expects to report preliminary data in the first half of next year.